Document:

November
23, 2018

 

Activa
Clinics

6610
Turner Valley Road, Suite 200

Mississauga,
Ontario L5N 2Pl

 

Attention:
Neil Dhalla

 

RE:
Binding Letter of Intent for the Acquisition, by Novo Healthnet Limited, of 100% of the issued and outstanding equity stock of
Activa Clinics in exchange for Common Stock of Novo Integrated Sciences Inc.

 

This
binding letter of intent (“LOI” or “Letter”) is to generally record terms and conditions
of the proposed agreement whereby Novo Integrated Sciences Inc., a Nevada corporation (“NVOS”) and Novo Healthnet
Limited, a wholly owned Canadian subsidiary of NVOS (“NHL”), will acquire all of the issued and outstanding
shares of Activa Clinics, a limited company incorporated under the laws of Ontario (“AC”), in exchange for
common shares of Novo Integrated Sciences, Inc. (the “Transaction”). This Letter represents only our good-faith
intention to negotiate and enter into a definitive agreement in a form acceptable to NVOS, NHL and AC.

 

This
Letter is a binding agreement between us. Notwithstanding the foregoing, the parties acknowledge and confirm it is their intention
that this Letter will serve only as a preliminary interim agreement in relation to the matters described herein, which will apply
until the Definitive Agreement (as defined below) is concluded.

 

Statements
below as to what we, or you, will do, or agree to do, or the like, are so expressed for convenience only, and are understood in
all instances (except for the items identified below in Section 11) to be subject to our mutual continued willingness to proceed
with the Transaction.

 

The
following paragraphs reflect our preliminary agreement with respect to the Transaction (as defined below):

 

	1.	Structure:
    The parties intend to enter into a share exchange or other similar business combination in which:

 

	 	(i)	NVOS
    will issue, based on a valuation of AC purchase price of 35 million CAD, the equivalent in NVOS common shares based on the
    30-trading day average share price for the period ending on the date of execution of this LOI to include the application of
    a market acceptable discount to the determined average, in exchange for all issued and outstanding shares held by the shareholders
    of AC. The shares issued to AC will be subject to a two-year lock up coinciding with the claw-back identified in Section 1(viii)
    of this Agreement. In the event the claw-back is waived prior to the two-year claw-back term, the lock-up will be removed
    and normal rule 144 restrictions will apply.
	 	 	 
	 	(ii)	For
    the sake of clarity; the current shareholder structure is referenced in our filings.

 

11120
NE 2nd Street, Suite 200 Bellevue, WA 98004 USA

Phone:
(206) 617-9797

www.novointegrated.com

 

    	 	 	 

    	Page | 2

    

 

	 	(iii)	Upon
    completion of the Transaction, NHL will hold all the issued and outstanding shares of AC and AC shall be a wholly-owned subsidiary
    of NHL.
	 	 	 
	 	(iv)	AC
    will have the right to appoint a board member to the NVOS Board of Directors.
	 	 	 
	 	(v)	NVOS-NHL
    will have the right to appoint a board member to the AC Board of Directors.
	 	 	 
	 	(vi)	Performance
    bonuses related to proprietary SOP’s and other AC intellectual property will be identifiable in a definitive agreement.
	 	 	 
	 	(vii)	Each
    AC shareholders shall enter into an employment agreement for a period of no less than two years from the close of the transaction.
    The employment agreement will identify specific bonus structures related to subsidiary revenue performance as well as total
    corporate performance.
	 	 	 
	 	(viii)	AC
    has the right to exercise a ‘ claw-back’ within a two-year period commencing the date of the closing of this transaction.
    The claw-back will result in the mutual return of AC and NVOS shares to the respective parties should targets not be met by
    NVOS as identified in a definite agreement.

 

	2.	Due
    Diligence: The parties will work promptly to carry out all required due diligence in respect of the proposed Transaction
    including without limitation, the completion of standard business, legal and other inquiries and a review of applicable laws
    and regulations. The parties will afford each other, its employees, auditors, legal counsel, and other authorized representatives
    all reasonable opportunity and access during normal business hours to inspect and investigate the business and financial affairs
    of the other party.
	 	 
	3.	Definitive
    Agreement. We mutually agree to proceed reasonably and in good faith toward the negotiation and execution of definitive
    documentation which shall contain the terms and conditions set out in the LOI and such other terms, conditions, indemnities,
    representations, warranties, covenants as are customary for transactions of this nature (the “Definitive Agreement”).
    The parties shall cooperate in structuring the Transaction in the most effective manner having regard to applicable tax,
    corporate, and securities laws. Upon the execution and delivery of the Definitive Agreement, it will supersede this Letter.
	 	 
	4.	Regulatory
    Approvals and Contractual Consents: Each of the parties will use its commercially reasonable best efforts to obtain:

 

	 	(i)	the
    necessary board approvals and shareholder approvals for the Transaction prior to the execution of the Definitive Agreement;
    and
	 	 	 
	 	(ii)	all
    necessary regulatory approvals (including approvals from any licensing authorities) and third-party consents and the necessary
    shareholder approvals prior to the closing of the Transaction and to cooperate in providing any submissions necessary to affect
    the Transaction.

 

	5.	Other
    Conditions. The Definitive Agreement shall include, but will not be limited to, the following:

 

	 	(i)	the
    parties having completed a due diligence investigation the results of which are satisfactory to the parties their sole discretion;

 

    	 	 	 

    	Page | 3

    

 

	 	(ii)	at
    the time of the Transaction, AC will have no liabilities, contingent or otherwise, unless such liabilities have been specifically
    agreed to by NHL in writing;
	 	 	 
	 	(iii)	AC
    will not be debarred or lose its status with any third-party or government payor/services for the provision of medical services
    because of the Transaction;
	 	 	 
	 	(iv)	AC
    will have received all regulatory approvals required to complete the Transaction;
	 	 	 
	 	(v)	the
    parties agree to cooperate to prepare for filing the necessary current reports with the Securities and Exchange Commission
    with respect to the Transaction, including a Form 8-K/A, within the regulatory required time limits following the closing
    of the Transaction;
	 	 	 
	 	(vi)	the
    representations and warranties of contained herein shall be true and correct in all material respects as of the closing of
    the Transaction; and
	 	 	 
	 	(vii)	no
    material adverse change shall have occurred in the business, assets, liabilities, results, financial condition, affairs or
    prospects of AC from the date hereof to the closing of the Transaction.

 

	6.	Adjustment
    of Officers and Directors: At the closing of the Transaction, both parties will appoint directors to each other’s
    boards as described above.
	 	 
	7.	Confidentiality:
    Each party agrees that, subject to compliance with applicable laws, it will keep confidential, and not release to any
    other person, this proposal, the contents of this Binding Letter of Intent and any of the proprietary business, technical
    or other information obtained by it during its due diligence inquiries and any related negotiations. Each party’s obligations
    in this respect shall survive the closing of the Transaction or any termination of the proposed Transaction between the parties
    or the termination of this LOI.
	 	 
	8.	Disclosure:
    No public announcement concerning the Transaction contemplated herein or the status of the discussions between the parties
    hereto shall be made by either party unless and until the same has been approved by both parties hereto, unless such disclosure
    is required by any government laws, rules or regulations, by any government regulatory authorities or any stock exchange
    having jurisdiction over either party provided prior written notice is provided to the other party respecting such disclosure
    or public announcement and such party has been provided reasonable opportunity to review and comment on the proposed disclosure.
	 	 
	9.	Costs:
    The parties will each be solely responsible for and bear their own respective expenses, including, without limitation,
    expenses of legal counsel, accountants, and other advisors, incurred at any time in connection with pursuing or consummating
    the Transaction. Each party’s obligations in this respect shall survive the closing of the Transaction or any termination
    of the proposed Transaction between the parties. It is expressly understood that both parties’ counsel will be together,
    responsible for preparing the documents required to complete the Transaction including the filing statement required to be
    filed with the Securities and Exchange Commission in connection with the Transaction.

 

    	 	 	 

    	Page | 4

    

 

	10.	Exclusivity:
    The parties hereby agree that until the Termination Date (as defined below) and the date the parities enter into the Definitive
    Agreement, that neither party, their respective directors, officers, agents and representatives will not, directly or indirectly:

 

	 	(i)	solicit,
    initiate or encourage the initiation of any expression of interest, inquiries or proposals regarding, constituting or that
    may reasonably be expected to lead to any merger, amalgamation, take-over bid, tender offer, arrangement, recapitalization,
    liquidations dissolution, share exchange, sale of material assets involving the parties or a proposal or offer to do so (the
    “Acquisition Proposal”) (including without limitation, any grant of an option or other right to take any
    such action);
	 	 	 
	 	(ii)	participate
    in any discussions or negotiations regarding an Acquisition Proposal;
	 	 	 
	 	(iii)	accept
    or enter into, or propose publicly to accept or enter into, any agreement, letter of intent, memorandum of understanding or
    any arrangement in respect of an Acquisition Proposal; and
	 	 	 
	 	(iv)	otherwise
    cooperate in any way, assist or participate in, facilitate or encourage any effort or attempt by any person to do any of the
    foregoing.

 

	11.	Binding
    Effect: The consummation of the Transaction is subject to the entry of the Definitive Agreement. The Definitive Agreement
    is subject to the board approval of each of the parties.
	 	 
	12.	Termination:
    If the Definitive Agreement is not negotiated and executed by both parties on or before December 31st, 2018 or such other
    date as agreed to by the parties, (the “Termination Date”) the terms of this LOI will be of no further
    force or effect except for Section 7 (Confidentiality), Section 9 (Costs) and Section 13 (Governing Laws). Section 7 (Confidentiality)
    and Section 13 (Governing Laws) will remain in effect for a period of one (1) year following the date this LOI is terminated.
	 	 
	13.	Governing
    Laws: This Letter of Intent will be governed by and be construed in accordance with the laws of the Province of Ontario
    and the federal laws of Canada applicable therein. The parties agree that any dispute arising out of or relating to this LOI
    shall be subject to the exclusive jurisdiction of the courts in and for the Province of Ontario and each party agrees to submit
    to the personal and exclusive jurisdiction and venue of such courts. Governing law and jurisdiction regarding the Definitive
    Agreement shall be negotiated between and agreed to by the parties and set out in the Definitive Agreement.

 

If
the terms outlined above are acceptable to you please sign and date this Letter in the space provided below and return a signed
copy to the undersigned.

 

	 	Very
    truly yours,
	 	 
	 	By:	/s/
    Robert     Mattacchione
	 	 	Robert
    Mattacchione
	 	 	CEO,
    Novo Integrated Sciences, Inc.
	 	 	Chairman,
    Novo Healthnet Limited
	 	 	 
	 	ACKNOWLEDGED
    AND AGREED to on 11/23/18
	 	 	 
	 	By:	/s/
    Dr.     Neil Dhalla
	 	 	Dr.
    Neil Dhalla
	 	 	CEO,
    Activa ClinicsEX-4.1

 Exhibit 4.1 
  

UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION
(“DTC”), TO ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC
(AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE, OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE
REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. 
 UNLESS AND UNTIL THIS CERTIFICATE IS EXCHANGED IN WHOLE OR IN PART
FOR NOTES IN CERTIFICATED FORM, THIS CERTIFICATE MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY DTC TO A NOMINEE THEREOF OR BY A NOMINEE THEREOF TO DTC OR ANOTHER NOMINEE OF DTC OR BY DTC OR ANY SUCH NOMINEE TO A SUCCESSOR OF DTC OR A NOMINEE OF SUCH
SUCCESSOR. 
  

					
	 REGISTERED
	  	 	REGISTERED	 
	 NO. 001
	  	 	PRINCIPAL AMOUNT	 
		
	 CUSIP No. 26884A BK8
	  	 	$400,000,000	 

 ERP OPERATING LIMITED PARTNERSHIP 

4.150% Notes due December 1, 2028 

ERP Operating Limited Partnership, an Illinois limited partnership (the “Issuer,” which term includes any successor under the
Indenture hereinafter referred to), for value received, hereby promises to pay to Cede & Co. or registered assigns, the principal sum of Four Hundred Million Dollars on December 1, 2028 (the “Maturity Date”), and to pay
interest thereon from December 1, 2018 (or from the most recent Interest Payment Date to which interest has been paid or duly provided for), semi annually in arrears on June 1 and December 1 of each year (each, an “Interest
Payment Date”), commencing on June 1, 2019, and on the Maturity Date, at the rate of 4.150% per annum, until payment of said principal sum has been made or duly provided for. 

The interest so payable and punctually paid or duly provided for on any Interest Payment Date and on the Maturity Date will be paid to the
Holder in whose name this Note (or one or more predecessor Notes) is registered at the close of business on the “Record Date” for such payment, which will be the May 15 or November 15 next preceding such Interest Payment Date, or
the Maturity Date, as the case may be. Any interest not so punctually paid or duly provided for shall forthwith cease to be payable to the Holder on such Record Date, and shall be paid to the Holder in whose name this Note (or one or more
predecessor Notes) is registered at the close of business on a subsequent record date for the payment of such defaulted interest (which shall be not more than 15 days and not less than 10 days) prior to the date of the payment of such defaulted
interest) established by notice given by mail by or on behalf of the Issuer to the Holders of the Notes not less than ten days preceding such subsequent record date. Interest on this Note will be computed on the basis of a 360-day year of twelve 30-day months. 
 The principal of this
Note payable on the Maturity Date will be paid against presentation and surrender of this Note at the office or agency of the Issuer maintained for that purpose in the Borough of Manhattan, the City of New York. The Issuer hereby initially
designates the Corporate Trust Office of the Trustee in the City of Chicago, and the office or agency of the Trustee in the Borough of Manhattan, the City of New York, as the offices to be maintained by it where Notes may be presented for payment,
registration of transfer or exchange and where notices or demands to or upon the Issuer in respect of the Notes or the Indenture referred to on the reverse hereof may be served. 

Interest payable on this Note on any Interest Payment Date and on the Maturity Date, as the case may be, will be the amount of interest
accrued from and including the immediately preceding Interest Payment Date (or from and including December 1, 2018, in the case of the initial Interest Payment Date) to but excluding the applicable Interest Payment Date or the Maturity Date, as
the case may be. If any Interest Payment Date other than the Maturity Date would otherwise be a day that is not a Business Day (as defined below), such Interest Payment Date will be postponed to the succeeding Business

 
Day. If the Maturity Date falls on a day that is not a Business Day, principal and interest payable on the Maturity Date will be paid on the succeeding Business Day with the same force and effect
as if it were paid on the date such payment was due, and no interest will accrue on the amount so payable for the period from and after the Maturity Date. “Business Day” means any day, other than a Saturday or Sunday, that is neither a
legal holiday nor a day on which banking institutions in the City of New York or the City of Chicago are authorized or required by law, regulation or executive order to close. 

Payments of principal and interest in respect of this Note will be made to the registered Holder of this Note in such coin or currency as at
the time of payment is legal tender for the payment of public and private debts. 
 Reference is made to the further provisions of this Note
set forth on the reverse hereof. Such further provisions shall for all purposes have the same effect as though fully set forth at this place. 

This Note shall not be entitled to the benefits of the Indenture referred to on the reverse hereof or be valid or become obligatory for any
purpose until the certificate of authentication hereon shall have been signed by the Trustee under such Indenture. 

*    *    *    *    * 

 IN WITNESS WHEREOF, the Issuer has caused this instrument to be signed manually or by
facsimile by its duly authorized officers. 
  

					
	Dated: _____________, 2018	 	ERP OPERATING LIMITED PARTNERSHIP, as Issuer
			
		 	By:	 	 EQUITY RESIDENTIAL,
 not individually but as
General Partner

			
		 	By:	 	  

		 		 	Robert A. Garechana
		 	Its:	 	Executive Vice President and Chief Financial Officer
			
		 	By:	 	  

		 		 	Scott J. Fenster
		 	Its:	 	Executive Vice President, General Counsel and Corporate Secretary

 TRUSTEE’S CERTIFICATE OF AUTHENTICATION 

This is one of the Securities of the series designated herein referred to in the within-mentioned Indenture. 

 

					
	 Dated: _____________, 2018
	 	 THE BANK OF NEW YORK MELLON TRUST

COMPANY, N.A., as Trustee

			
		 	 By:
	 	  

		 		 	Authorized Signatory

 [REVERSE OF NOTE] 

ERP OPERATING LIMITED PARTNERSHIP 

4.150% Notes due December 1, 2028 

This Note is one of a duly authorized issue of debentures, notes, bonds, or other evidences of indebtedness of the Issuer (hereinafter called
the “Securities”) of the series hereinafter specified, all issued or to be issued under and pursuant to (i) an Indenture dated as of October 1, 1994 as supplemented from time to time (herein called the “Indenture”),
duly executed and delivered by the Issuer to The Bank of New York Mellon Trust Company, N.A. (formerly known as The Bank of New York Trust Company, N.A.) (as successor to J.P. Morgan Trust Company, National Association, as successor to Bank One
Trust Company, N.A., as successor to The First National Bank of Chicago) as Trustee (herein called the “Trustee,” which term includes any successor trustee under the Indenture with respect to the series of Securities of which this Note is
a part), and (ii) an Officers’ Certificate dated the date hereof (the “Officers’ Certificate”), duly executed by authorized officers of the Issuer, pursuant to Section 301 of the Indenture to which Officers’
Certificate and Indenture and all Indentures supplemental thereto reference is hereby made for a description of the rights, limitations of rights, obligations, duties, and immunities thereunder of the Trustee, the Issuer, and the Holders of the
Securities, and of the terms upon which the Securities are, and are to be, authenticated and delivered. The Securities may be issued in one or more series, which different series may be issued in various aggregate principal amounts, may mature at
different times, may bear interest (if any) at different rates, may be subject to different redemption provisions (if any), and may otherwise vary as provided in the Indenture. This Note is one of a series designated as the 4.150% Notes due
December 1, 2028 of the Issuer (the “Notes”). Subject to being increased by the Issuer pursuant to an Officers’ Certificate, the Notes are limited in aggregate principal amount to $400,000,000 (except as provided in the
Indenture). 
 If an Event of Default with respect to the Notes occurs and is continuing, the principal hereof and Make-Whole Amount (if
any) may be declared, and upon such declaration shall become, due and payable, in the manner, with the effect, and subject to the conditions provided in the Indenture. 

Prior to September 1, 2028 (the date that is three months prior to the maturity date of the Notes), the Issuer may redeem the Notes, at
any time in whole or from time to time in part, at the election of the Issuer, at a redemption price equal to the sum of (i) the principal amount of the Notes being redeemed plus accrued interest thereon to the Redemption Date and (ii) the
Make-Whole Amount, if any, with respect to the Notes. For purposes of the Notes, the Reinvestment Rate will be determined using 0.200% as specified in the Officers’ Certificate in lieu of the percentage contained in the Indenture. On or after
September 1, 2028 (the date that is three months prior to the maturity date of the Notes), the Issuer may redeem the Notes, at any time in whole or from time to time in part, at the election of the Issuer, at a redemption price equal to the
principal amount of the Notes being redeemed plus accrued interest thereon to the Redemption Date. Notice of any optional redemption of any Notes will be given to Holders at their addresses, as shown in the Security Register, not more than 45 nor
less than 15 days prior to the date fixed for redemption. The notice of redemption will specify, among other items, the redemption price and the principal amount of the Notes held by such Holder to be redeemed. 

The Indenture contains provisions for defeasance of (i) the entire indebtedness of the Notes or (ii) certain covenants (specifically
including the covenants in the third supplemental indenture dated as of June 4, 2007, by and between the Issuer and the Trustee, as modified by the fourth supplemental indenture dated as of December 12, 2011, by and between the Issuer and
the Trustee) and events of default with respect to the Notes in the Indenture in each case upon compliance with Article Fourteen of the Indenture, which provisions apply to the Notes. 

The Indenture contains provisions permitting the Issuer and the Trustee, with the consent of the Holders of not less than a majority of the
aggregate principal amount of all Outstanding Securities affected by such supplemental indenture, to execute supplemental Indentures adding any provisions to or changing in any manner or eliminating any of the provisions of the Indenture or
modifying in any manner the rights of the Holders of Securities under the Indenture; provided, however, that no such supplemental Indenture shall, without the consent of the Holder of each Outstanding Security so affected, (i) change the stated
maturity of the principal of (or premium, if any), or any installment of principal of or interest on, any Security, (ii) reduce the principal amount of, or the rate or amount of interest on, or premium payable upon the redemption of, any
Security, (iii) change the place of payment, or the currency, for payment of principal of any Security or any premium or interest on any Security, (iv) impair the right to institute suit for the enforcement of any

 
payment on or with respect to any Security on or after the stated maturity thereof (or in the case of redemption, on or after the redemption date), (v) reduce the above-stated percentage of
Outstanding Securities of any series necessary to modify or amend the Indenture, to waive compliance with certain provisions thereof or certain defaults and consequences thereunder or to reduce the quorum or voting requirements set forth in the
Indenture, or (vi) modify any of the foregoing provisions or any provisions relating to the waiver of certain past defaults or certain covenants, except to increase the required percentage to effect such action or to provide that certain other
provisions may not be modified or waived without the consent of the Holders or each Outstanding Security affected thereby. It is also provided in the Indenture that, with respect to certain defaults or Events of Default regarding the Securities of
any series, the Holders of not less than a majority in aggregate principal amount outstanding of the Securities of such series may on behalf of the Holders of all the Securities of such series waive any such past default or Event of Default and its
consequences, prior to any declaration accelerating the maturity of such Securities; or, subject to certain conditions, may rescind a declaration of acceleration and its consequences with respect to such Securities. Any such consent or waiver by the
Holder of this Note (unless revoked as provided in the Indenture) shall be conclusive and binding upon such Holder and upon all future Holders and owners of this Note and any securities that may be issued in exchange or substitution herefor,
irrespective of whether or not any notation thereof is made upon this Note or such other securities. 
 No reference herein to the Indenture
and no provision of this Note or of the Indenture shall alter or impair the obligation of the Issuer, which is absolute and unconditional, to pay the principal of and any Make-Whole Amount and interest on this Note in the manner, at the respective
times, at the rate and in the coin or currency herein prescribed. 
 This Note is issuable only in registered form without coupons in
denominations of $1,000 and integral multiples thereof. Securities may be exchanged for a like aggregate principal amount of Securities of this series of other authorized denominations at the office or agency of the Issuer maintained for that
purpose at the Corporate Trust Office of the Trustee in the City of Chicago, and the office or agency of the Trustee in the Borough of Manhattan, the City of New York, in the manner and subject to the limitations provided in the Indenture, but
without the payment of any service charge except for any tax or other governmental charge imposed in connection therewith. 
 Upon due
presentment for registration of transfer of Securities at the office or agency of the Issuer maintained for that purpose at the Corporate Trust Office of the Trustee in the City of Chicago, or the office or agency of the Trustee in the Borough of
Manhattan, the City of New York, a new Security or Securities of the same series of authorized denominations in an equal aggregate principal amount will be issued to the transferee in exchange therefor, subject to the limitations provided in the
Indenture, without charge except for any tax or other governmental charge imposed in connection therewith. 
 The Issuer, the Trustee, and
any authorized agent of the Issuer or the Trustee may deem and treat the Person in whose name this Note is registered as the absolute owner of this Note (whether or not this Note shall be overdue and notwithstanding any notation of ownership or
other writing hereon), for the purpose of receiving payment of, or on account of, the principal hereof and Make-Whole Amount, if any, and subject to the provisions on the face hereof, interest hereon, and for all other purposes, and neither the
Issuer nor the Trustee nor any authorized agent of the Issuer or the Trustee shall be affected by any notice to the contrary. 
 The
Indenture and each Security shall be deemed to be a contract under the laws of the State of New York, and for all purposes shall be governed by and construed in accordance with the law of the State of New York. 

Terms used herein that are defined in the Indenture shall have the respective meanings assigned thereto in the Indenture.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}]]